Dose-Response of Simvastatin in Primary Hypercholesterolemia

Tuomilehto, J; Ac, Guimarães; Kettner, Hannes; Lithell, Hans; Pitkänen, Matti; Sailer, D; Lf, Van Gaal

doi:10.1097/00005344-199424060-00012

Cited by 17 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these studies, adding ezetimibe 10 mg day x1 to simvastatin 10 or 20 day x1 demonstrated additional LDL-C reductions of 17-18%, similar to reductions one might expect from titrating three times with a statin (e.g. from 10 mg to 80 mg of simvastatin) [35]. Unlike the preclinical findings, the incremental reduction in mean LDL-C achieved by the coadministration of ezetimibe 10 mg and simvastatin 10 or 20 mg appears to be additive rather than synergistic.…”

Section: Discussionsupporting

confidence: 56%

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

Kosoglou¹,

Meyer²,

Musiol³

et al. 2000

Atherosclerosis

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 56%

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

Kosoglou¹,

Meyer²,

Musiol³

et al. 2000

Atherosclerosis

View full text Add to dashboard Cite

“…For example, in a multicenter randomized double-blind placebo-control trial, when patients received 2.5, 5, and 10 mg of amlodipine, target blood pressure goals were reached in 41%, 56%, and 73% of patients, respectively. 47 Similar linear dose responses have been observed for lisinopril, 48 simvastatin, 49 valsartan, 50 and dabigatran. 51 Diet studies exhibit dose-response associations as well.…”

Section: Discussionsupporting

confidence: 64%

Once-Daily Low Inflammatory Foods Everyday (LIFE) Smoothie or the Full LIFE Diet Lowers C-Reactive Protein and Raises Plasma Beta-Carotene in 7 Days

Perzia

Ying

Dunaief

et al. 2020

American Journal of Lifestyle Medicine

View full text Add to dashboard Cite

Serum C-reactive protein (CRP), a marker of systemic inflammation, is associated with increased risk for numerous inflammation-driven chronic diseases. A prior longitudinal study showed that the Low Inflammatory Foods Everyday (LIFE) diet, which is rich in dark green leafy vegetables (DGLV), lowered CRP over a mean follow-up period of 6 months. In this retrospective study, we investigate whether patients who consume the LIFE diet or their regular diet plus one component of the LIFE diet (LIFE smoothie), experience reductions in high-sensitivity CRP (hsCRP) in 7 days. Sixteen patients in a community practice met inclusion criteria. Patient compliance was assessed by patient interviews and measurements of beta-carotene, which is abundant in DGLV. Following the interventions, CRP decreased in both the LIFE diet (−0.47 mg/L, P = .02) and smoothie groups (−1.2 mg/L, P = .04). No statistically significant difference in reduction was observed between groups ( P = .18). Plasma beta-carotene increased in both groups (+23.2, P = .02; +20.6, P = .006, respectively). These findings suggest that the LIFE diet or a regular American diet supplemented with the LIFE smoothie may quickly reduce systemic inflammation and the risk of many chronic diseases.

show abstract

“…Most recently, Gee et al measured laboratory lipids and liver enzyme levels in 512 patients who were enrolled in a HMG Co-A reductase inhibitor tablet-splitting program, where 85% of the patients were treated with simvastatin, as described above. 15 These 3 studies, along with the present splittablet results and wide therapeutic index of simvastatin, 19 support the mandatory tablet-split policy for simvastatin.…”

Section: Simvastatin: Clinical Considerationssupporting

confidence: 53%

Weight Uniformity of Split Tablets Required by a Veterans Affairs Policy

Polli

Kim²,

Martin³

2003

JMCP

View full text Add to dashboard Cite

OBJECTIVE: To split several tablet products relevant to the Veterans Affairs (VA) Maryland Healthcare System and assess whether the resulting half tablets provide equal doses.METHODS: From a VA list of products that are required to be split, 7 products were evaluated, along with 5 other commonly split tablet products. A trained pharmacy student split tablets using a tablet splitter provided by the VA. Half tablets were assessed for weight uniformity.RESULTS: Of the 12 products subjected to splitting, 8 products (atorvastatin, citalopram, furosemide, glipizide, metoprolol, paroxetine, sertraline, and warfarin) yielded half tablets that passed the weight-uniformity test. The 4 failing products were lisinopril, lovastatin, rofecoxib, and simvastatin. Unusual tablet shape and high tablet hardness predisposed products to failing the weight-uniformity test. The 4 failing products resulted in half tablets that were generally within 20% of their target weight range, suggesting that splitting these specific products would not result in adverse therapeutic effects due to dose variation created by tablet-splitting.CONCLUSION: Split-tablet results were relatively favorable and generally support a VA practice to split specific tablets. Public quality standards for half tablets, including their content uniformity, are needed to better delineate the policies for acceptable tablet splitting.

show abstract

Dose-Response of Simvastatin in Primary Hypercholesterolemia

Cited by 17 publications

References 0 publications

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

Once-Daily Low Inflammatory Foods Everyday (LIFE) Smoothie or the Full LIFE Diet Lowers C-Reactive Protein and Raises Plasma Beta-Carotene in 7 Days

Weight Uniformity of Split Tablets Required by a Veterans Affairs Policy

Contact Info

Product

Resources

About